Floatz logo

rg4733

Stage IV Skin Melanoma

National Cancer Institute (NCI)Phase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Stage IV Skin Melanoma cohort.

Asset / SponsorPhaseRating
na17.a2 peptide vaccine
National Cancer Institute (NCI)
Phase 2CCC
VINBLASTINE
National Cancer Institute (NCI)
Phase 1/2CCC
Tcr Transduced T-Cells
The Netherlands Cancer Institute
Phase 1/2CCC
mk-3475
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC
Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Mayo Clinic
Early Phase 1CC

Same molecule, other indications

rg4733 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
male breast carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →